Drosomycin is an inducible antifungal peptide of 44 residues initially isolated from bacteria-challenged Drosophila melanogaster. The systemic expression of drosomycin is regulated by the Toll pathway present in fat body, whereas inducible local expression in the respiratory tract is controlled by the Immune Deficiency (IMD) pathway. Drosomycin belongs to the cysteinestabilized a-helical and b-sheet (CSab) superfamily and is composed of an a-helix and a three-stranded bsheet stabilized by four disulphide bridges. Drosomycin exhibits a narrow antimicrobial spectrum and is only active against some filamentous fungi. However, recent work using recombinant drosomycin expressed in Escherichia coli revealed its antiparasitic and anti-yeast activities. Two evolutionary epitopes (a-and g-patch) and the m-loop have been proposed as putative functional regions of drosomycin for interaction with fungi and parasites, respectively. Similarity in sequence, structure and biological activity suggests that drosomycin and some defensin molecules from plants and fungi could originate from a common ancestor.

Family members may act as treatment supporters for MDR-TB patients to reduce treatment interruptions, but require orientation on their role.

ABSTRACT.Recently, studies on the pathogenesis of dilated cardiomyopathy (DCM) have focused on the underlying molecular biology and the association between single nucleotide polymorphisms (SNPs) and disease. This study was designed to explore the association between the rs4641 SNP of the LMNA gene and DCM in order to identify a new gene locus related to DCM. Polymerase chain reaction-restriction fragment length polymorphism and DNA sequencing were employed to detect and genotype rs4641 in 198 patients with DCM and 160 healthy controls. Genotype and allele frequencies were compared to discover their relationship and logistic regression was used to assess the risk of DCM associated with the polymorphic variants. In the DCM group, the frequencies of the TC (2015) and TT genotypes and the T allele of rs4641 were remarkably higher than those in the control group (P < 0.01). According to risk analysis, taking the CC genotype as a reference, both the TC and TT genotypes increased the risk of DCM pathogenesis, with OR (95%CI) values of 5.957 (2.903-12.222) and 6.424 (2.156-19.141), respectively. Taking the C allele as the reference, presence of the T allele was found to increase DCM risk, with OR (95%CI) of 5. 295 (3.121-8.983). These results suggested that the C to T mutation at the rs4641 locus of LMNA could enhance the risk of DCM, and that rs4641 represented a genetic susceptibility locus. Therefore, it was concluded that the LMNA rs4641 SNP was associated with DCM risk, which indicated that LMNA is a susceptibility gene for DCM.